-DOCSTART- -X- O
Rift -X- _ O
Valley -X- _ O
fever -X- _ O
virus -X- _ O
( -X- _ O
RVFV -X- _ O
; -X- _ O
genus -X- _ O
Phlebovirus -X- _ O
, -X- _ O
family -X- _ O
Bunyaviridae -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
mosquito-borne -X- _ O
zoonotic -X- _ O
pathogen -X- _ O
which -X- _ O
can -X- _ O
cause -X- _ O
hemorrhagic -X- _ O
fever -X- _ O
, -X- _ O
neurological -X- _ O
disorders -X- _ O
or -X- _ O
blindness -X- _ O
in -X- _ O
humans -X- _ O
, -X- _ O
and -X- _ O
a -X- _ O
high -X- _ O
rate -X- _ O
of -X- _ O
abortion -X- _ O
in -X- _ O
ruminants. -X- _ O
MP-12 -X- _ B-Intervention
strain -X- _ I-Intervention
, -X- _ O
a -X- _ O
live-attenuated -X- _ O
candidate -X- _ O
vaccine -X- _ O
, -X- _ O
is -X- _ O
attenuated -X- _ O
in -X- _ O
the -X- _ O
M- -X- _ O
and -X- _ O
L-segments -X- _ O
, -X- _ O
but -X- _ O
the -X- _ O
S-segment -X- _ O
retains -X- _ O
the -X- _ O
virulent -X- _ O
phenotype. -X- _ O
MP-12 -X- _ B-Intervention
was -X- _ O
manufactured -X- _ O
as -X- _ O
an -X- _ O
Investigational -X- _ O
New -X- _ O
Drug -X- _ O
vaccine -X- _ O
by -X- _ O
using -X- _ O
MRC-5 -X- _ O
cells -X- _ O
and -X- _ O
encodes -X- _ O
a -X- _ O
functional -X- _ O
NSs -X- _ O
gene -X- _ O
, -X- _ O
the -X- _ O
major -X- _ O
virulence -X- _ O
factor -X- _ O
of -X- _ O
RVFV -X- _ O
which -X- _ O
1 -X- _ O
) -X- _ O
induces -X- _ O
a -X- _ O
shutoff -X- _ O
of -X- _ O
the -X- _ O
host -X- _ O
transcription -X- _ O
, -X- _ O
2 -X- _ O
) -X- _ O
inhibits -X- _ O
interferon -X- _ O
( -X- _ O
IFN -X- _ O
) -X- _ O
-β -X- _ O
promoter -X- _ O
activation -X- _ O
, -X- _ O
and -X- _ O
3 -X- _ O
) -X- _ O
promotes -X- _ O
the -X- _ O
degradation -X- _ O
of -X- _ O
dsRNA-dependent -X- _ O
protein -X- _ O
kinase -X- _ O
( -X- _ O
PKR -X- _ O
) -X- _ O
. -X- _ O
MP-12 -X- _ B-Intervention
lacks -X- _ O
a -X- _ O
marker -X- _ O
for -X- _ O
differentiation -X- _ O
of -X- _ O
infected -X- _ O
from -X- _ O
vaccinated -X- _ O
animals -X- _ O
( -X- _ O
DIVA -X- _ O
) -X- _ O
. -X- _ O
Although -X- _ O
MP-12 -X- _ O
lacking -X- _ O
NSs -X- _ O
works -X- _ O
for -X- _ O
DIVA -X- _ O
, -X- _ O
it -X- _ O
does -X- _ O
not -X- _ O
replicate -X- _ O
efficiently -X- _ O
in -X- _ O
type-I -X- _ O
IFN-competent -X- _ O
MRC-5 -X- _ O
cells -X- _ O
, -X- _ O
while -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
type-I -X- _ O
IFN-incompetent -X- _ O
cells -X- _ O
may -X- _ O
negatively -X- _ O
affect -X- _ O
its -X- _ O
genetic -X- _ O
stability. -X- _ O
To -X- _ O
generate -X- _ O
modified -X- _ O
MP-12 -X- _ O
vaccine -X- _ B-Intervention
candidates -X- _ I-Intervention
encoding -X- _ I-Intervention
a -X- _ I-Intervention
DIVA -X- _ I-Intervention
marker -X- _ I-Intervention
, -X- _ O
while -X- _ O
still -X- _ O
replicating -X- _ O
efficiently -X- _ O
in -X- _ O
MRC-5 -X- _ O
cells -X- _ O
, -X- _ O
we -X- _ O
generated -X- _ O
recombinant -X- _ B-Intervention
MP-12 -X- _ I-Intervention
encoding -X- _ I-Intervention
Punta -X- _ I-Intervention
Toro -X- _ I-Intervention
virus -X- _ I-Intervention
Adames -X- _ I-Intervention
strain -X- _ I-Intervention
NSs -X- _ I-Intervention
( -X- _ I-Intervention
rMP12-PTNSs -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ I-Intervention
Sandfly -X- _ I-Intervention
fever -X- _ I-Intervention
Sicilian -X- _ I-Intervention
virus -X- _ I-Intervention
NSs -X- _ I-Intervention
( -X- _ I-Intervention
rMP12-SFSNSs -X- _ I-Intervention
) -X- _ I-Intervention
in -X- _ O
place -X- _ O
of -X- _ O
MP-12 -X- _ O
NSs. -X- _ O
We -X- _ O
have -X- _ O
demonstrated -X- _ O
that -X- _ O
those -X- _ O
recombinant -X- _ B-Outcome
MP-12 -X- _ I-Outcome
viruses -X- _ I-Outcome
inhibit -X- _ I-Outcome
IFN-β -X- _ I-Outcome
mRNA -X- _ I-Outcome
synthesis -X- _ I-Outcome
, -X- _ I-Outcome
yet -X- _ I-Outcome
do -X- _ I-Outcome
not -X- _ I-Outcome
promote -X- _ I-Outcome
the -X- _ I-Outcome
degradation -X- _ I-Outcome
of -X- _ I-Outcome
PKR. -X- _ I-Outcome
The -X- _ I-Outcome
rMP12-PTNSs -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
rMP12-SFSNSs -X- _ I-Outcome
, -X- _ I-Outcome
replicated -X- _ I-Outcome
more -X- _ I-Outcome
efficiently -X- _ I-Outcome
than -X- _ I-Outcome
recombinant -X- _ I-Outcome
MP-12 -X- _ I-Outcome
lacking -X- _ I-Outcome
NSs -X- _ I-Outcome
in -X- _ I-Outcome
MRC-5 -X- _ I-Outcome
cells. -X- _ I-Outcome
Mice -X- _ I-Outcome
vaccinated -X- _ I-Outcome
with -X- _ I-Outcome
rMP12-PTNSs -X- _ I-Outcome
or -X- _ I-Outcome
rMP12- -X- _ I-Outcome
SFSNSs -X- _ I-Outcome
induced -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibodies -X- _ I-Outcome
at -X- _ I-Outcome
a -X- _ I-Outcome
level -X- _ I-Outcome
equivalent -X- _ I-Outcome
to -X- _ I-Outcome
those -X- _ I-Outcome
vaccinated -X- _ I-Outcome
with -X- _ I-Outcome
MP-12 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
were -X- _ I-Outcome
efficiently -X- _ I-Outcome
protected -X- _ I-Outcome
from -X- _ I-Outcome
wild-type -X- _ I-Outcome
RVFV -X- _ I-Outcome
challenge. -X- _ I-Outcome
The -X- _ I-Outcome
rMP12-PTNSs -X- _ I-Outcome
and -X- _ I-Outcome
rMP12-SFSNSs -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
induce -X- _ I-Outcome
antibodies -X- _ I-Outcome
cross-reactive -X- _ I-Outcome
to -X- _ I-Outcome
anti-RVFV -X- _ I-Outcome
NSs -X- _ I-Outcome
antibody -X- _ I-Outcome
and -X- _ I-Outcome
are -X- _ I-Outcome
therefore -X- _ I-Outcome
applicable -X- _ I-Outcome
to -X- _ I-Outcome
DIVA. -X- _ I-Outcome
Thus -X- _ I-Outcome
, -X- _ I-Outcome
rMP12-PTNSs -X- _ I-Outcome
is -X- _ I-Outcome
highly -X- _ I-Outcome
efficacious -X- _ I-Outcome
, -X- _ I-Outcome
replicates -X- _ I-Outcome
efficiently -X- _ I-Outcome
in -X- _ I-Outcome
MRC-5 -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
encodes -X- _ I-Outcome
a -X- _ I-Outcome
DIVA -X- _ I-Outcome
marker -X- _ I-Outcome
, -X- _ I-Outcome
all -X- _ I-Outcome
of -X- _ I-Outcome
which -X- _ I-Outcome
are -X- _ I-Outcome
important -X- _ I-Outcome
for -X- _ I-Outcome
vaccine -X- _ I-Outcome
development -X- _ I-Outcome
for -X- _ I-Outcome
Rift -X- _ I-Outcome
Valley -X- _ I-Outcome
fever -X- _ I-Outcome
. -X- _ O

